SUPPLEMENT

Q4 2021 — Sales of Key Products/Franchises

Q4 2021PDF · 6 pages199 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	633	$ 	543 	16.8% 	16.8% 	- 	2,594	$ 	2,460 	5.4% 	5.4% 	-
Intl 	740 	642 	15.1% 	14.9% 	0.2% 	2,634 	2,364 	11.4% 	6.9% 	4.5%
WW 	1,373 	1,185 	15.9% 	15.8% 	0.1% 	5,227 	4,824 	8.4% 	6.2% 	2.2%
SKIN HEALTH / BEAUTY
US 	538 	583 	-7.8% 	-7.8% 	- 	2,400 	2,350 	2.1% 	2.1% 	-
Intl 	546 	594 	-8.2% 	-6.4% 	-1.8% 	2,141 	2,100 	1.9% 	-0.3% 	2.2%
WW 	1,084 	1,177 	-8.0% 	-7.1% 	-0.9% 	4,541 	4,450 	2.0% 	1.0% 	1.0%
ORAL CARE
US 	159 	173 	-8.2% 	-8.2% 	- 	637 	683 	-6.7% 	-6.7% 	-
Intl 	246 	264 	-7.2% 	-5.5% 	-1.7% 	1,008 	958 	5.1% 	2.8% 	2.3%
WW 	405 	437 	-7.6% 	-6.5% 	-1.1% 	1,645 	1,641 	0.2% 	-1.2% 	1.4%
BABY CARE
US 	90 	97 	-7.5% 	-7.5% 	- 	378 	376 	0.5% 	0.5% 	-
Intl 	309 	310 	-0.3% 	1.3% 	-1.6% 	1,188 	1,141 	4.1% 	3.7% 	0.4%
WW 	399 	407 	-2.0% 	-0.8% 	-1.2% 	1,566 	1,517 	3.2% 	2.9% 	0.3%
WOMEN'S HEALTH
US 	4 	3 	14.1% 	14.1% 	- 	13 	13 	-1.6% 	-1.6% 	-
Intl 	230 	234 	-1.8% 	1.2% 	-3.0% 	905 	888 	1.8% 	2.0% 	-0.2%
WW 	233 	237 	-1.6% 	1.3% 	-2.9% 	917 	901 	1.8% 	1.9% 	-0.1%
WOUND CARE / OTHER
US 	106 	110 	-4.2% 	-4.2% 	- 	495 	480 	3.1% 	3.1% 	-
Intl 	57 	65 	-9.6% 	-10.2% 	0.6% 	243 	240 	1.7% 	-2.7% 	4.4%
WW 	164 	175 	-6.2% 	-6.4% 	0.2% 	739 	720 	2.6% 	1.2% 	1.4%
TOTAL CONSUMER HEALTH
US 	1,529 	1,509 	1.3% 	1.3% 	- 	6,516 	6,362 	2.4% 	2.4% 	-
Intl 	2,128 	2,109 	0.9% 	2.1% 	-1.2% 	8,119 	7,691 	5.6% 	3.1% 	2.5%
WW 	3,657	$ 	3,618 	1.1% 	1.8% 	-0.7% 	14,635	$ 	14,053 	4.1% 	2.8% 	1.3%
See footnotes at end of schedule
% Change 	% Change

-- 1 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
PHARMACEUTICAL SEGMENT (2,3) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	2,912	$ 	2,845 	2.4% 	2.4% 	- 	10,843	$ 	10,175 	6.6% 	6.6% 	-
Intl 	1,443 	1,261 	14.5% 	17.9% 	-3.4% 	5,907 	4,880 	21.0% 	17.7% 	3.3%
WW 	4,355 	4,105 	6.1% 	7.1% 	-1.0% 	16,750 	15,055 	11.3% 	10.2% 	1.1%
REMICADE
US 	511 	656 	-22.2% 	-22.2% 	- 	2,019 	2,508 	-19.5% 	-19.5% 	-
US Exports (4) 	39 	25 	53.5% 	53.5% 	- 	236 	346 	-31.9% 	-31.9% 	-
Intl 	214 	220 	-2.3% 	-2.4% 	0.1% 	935 	893 	4.8% 	0.4% 	4.4%
WW 	764 	901 	-15.2% 	-15.2% 	0.0% 	3,190 	3,747 	-14.9% 	-15.9% 	1.0%
SIMPONI / SIMPONI ARIA
US 	287 	315 	-8.9% 	-8.9% 	- 	1,127 	1,155 	-2.4% 	-2.4% 	-
Intl 	271 	261 	3.6% 	8.4% 	-4.8% 	1,148 	1,088 	5.5% 	4.1% 	1.4%
WW 	559 	576 	-3.2% 	-1.0% 	-2.2% 	2,276 	2,243 	1.4% 	0.8% 	0.6%
STELARA
US 	1,542 	1,572 	-1.9% 	-1.9% 	- 	5,938 	5,240 	13.3% 	13.3% 	-
Intl 	792 	672 	17.9% 	21.7% 	-3.8% 	3,196 	2,467 	29.6% 	25.9% 	3.7%
WW 	2,334 	2,244 	4.0% 	5.1% 	-1.1% 	9,134 	7,707 	18.5% 	17.3% 	1.2%
TREMFYA
US 	528 	276 	90.9% 	90.9% 	- 	1,503 	926 	62.3% 	62.3% 	-
Intl 	165 	105 	56.9% 	61.8% 	-4.9% 	624 	421 	48.2% 	44.0% 	4.2%
WW 	693 	382 	81.5% 	82.8% 	-1.3% 	2,127 	1,347 	57.9% 	56.5% 	1.4%
OTHER IMMUNOLOGY
US 	6 	- 	* 	* 	- 	21 	- 	* 	* 	-
Intl 	0 	2 	* 	* 	* 	3 	11 	-73.3% 	-74.6% 	1.3%
WW 	6 	2 	* 	* 	* 	24 	11 	* 	* 	*
INFECTIOUS DISEASES
US 	614 	470 	30.8% 	30.8% 	- 	2,249 	1,735 	29.7% 	29.7% 	-
Intl 	1,824 	442 	* 	* 	-3.0% 	3,612 	1,839 	96.3% 	93.4% 	2.9%
WW 	2,437 	912 	* 	* 	-1.5% 	5,861 	3,574 	64.0% 	62.5% 	1.5%
COVID-19 VACCINE
US 	213 	- 	* 	* 	- 	634 	- 	* 	* 	-
Intl 	1,405 	- 	* 	* 	- 	1,751 	- 	* 	* 	-
WW 	1,619 	- 	* 	* 	- 	2,385 	- 	* 	* 	-
EDURANT / rilpivirine
US 	10 	11 	-15.8% 	-15.8% 	- 	41 	44 	-7.6% 	-7.6% 	-
Intl 	220 	236 	-6.8% 	-3.3% 	-3.5% 	953 	920 	3.6% 	0.4% 	3.2%
WW 	230 	248 	-7.2% 	-3.9% 	-3.3% 	994 	964 	3.1% 	0.0% 	3.1%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	380 	433 	-12.2% 	-12.2% 	- 	1,508 	1,587 	-4.9% 	-4.9% 	-
Intl 	135 	136 	-0.1% 	3.0% 	-3.1% 	575 	597 	-3.6% 	-6.0% 	2.4%
WW 	515 	569 	-9.3% 	-8.5% 	-0.8% 	2,083 	2,184 	-4.6% 	-5.2% 	0.6%
OTHER INFECTIOUS DISEASES
US 	11 	25 	-55.9% 	-55.9% 	- 	66 	104 	-36.0% 	-36.0% 	-
Intl 	63 	71 	-10.9% 	-10.0% 	-0.9% 	333 	323 	3.0% 	-0.1% 	3.1%
WW 	74 	96 	-22.9% 	-22.2% 	-0.7% 	399 	427 	-6.5% 	-8.9% 	2.4%
% Change 	% Change

-- 2 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	899 	806 	11.4% 	11.4% 	- 	3,347 	3,091 	8.3% 	8.3% 	-
Intl 	894 	892 	0.2% 	3.2% 	-3.0% 	3,664 	3,457 	6.0% 	3.9% 	2.1%
WW 	1,793 	1,698 	5.5% 	7.1% 	-1.6% 	7,011 	6,548 	7.1% 	5.9% 	1.2%
CONCERTA / Methylphenidate
US 	55 	33 	68.1% 	68.1% 	- 	172 	183 	-5.8% 	-5.8% 	-
Intl 	123 	120 	3.2% 	6.0% 	-2.8% 	495 	439 	12.8% 	10.1% 	2.7%
WW 	178 	153 	17.2% 	19.4% 	-2.2% 	667 	622 	7.3% 	5.4% 	1.9%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	668 	610 	9.5% 	9.5% 	- 	2,550 	2,314 	10.2% 	10.2% 	-
Intl 	361 	355 	1.5% 	5.0% 	-3.5% 	1,472 	1,339 	10.0% 	6.9% 	3.1%
WW 	1,029 	965 	6.5% 	7.8% 	-1.3% 	4,022 	3,653 	10.1% 	9.0% 	1.1%
RISPERDAL CONSTA
US 	77 	76 	2.3% 	2.3% 	- 	287 	296 	-2.9% 	-2.9% 	-
Intl 	63 	92 	-30.3% 	-26.4% 	-3.9% 	305 	346 	-11.8% 	-13.1% 	1.3%
WW 	140 	167 	-15.6% 	-13.4% 	-2.2% 	592 	642 	-7.7% 	-8.4% 	0.7%
OTHER NEUROSCIENCE
US 	99 	88 	11.7% 	11.7% 	- 	338 	298 	13.3% 	13.3% 	-
Intl 	346 	326 	6.2% 	8.6% 	-2.4% 	1,391 	1,334 	4.3% 	3.2% 	1.1%
WW 	445 	414 	7.4% 	9.2% 	-1.8% 	1,729 	1,632 	6.0% 	5.0% 	1.0%
ONCOLOGY
US 	1,594 	1,469 	8.5% 	8.5% 	- 	5,958 	5,092 	17.0% 	17.0% 	-
Intl 	2,184 	1,965 	11.1% 	15.2% 	-4.1% 	8,590 	7,275 	18.1% 	15.3% 	2.8%
WW 	3,778 	3,434 	10.0% 	12.3% 	-2.3% 	14,548 	12,367 	17.6% 	16.0% 	1.6%
DARZALEX
US 	867 	692 	25.3% 	25.3% 	- 	3,169 	2,232 	42.0% 	42.0% 	-
Intl 	778 	561 	38.9% 	43.5% 	-4.6% 	2,854 	1,958 	45.8% 	42.6% 	3.2%
WW 	1,645 	1,253 	31.4% 	33.4% 	-2.0% 	6,023 	4,190 	43.8% 	42.3% 	1.5%
ERLEADA
US 	235 	176 	33.4% 	33.4% 	- 	813 	583 	39.3% 	39.3% 	-
Intl 	149 	64 	* 	* 	* 	478 	176 	* 	* 	*
WW 	384 	241 	59.8% 	61.3% 	-1.5% 	1,291 	760 	70.0% 	68.7% 	1.3%
IMBRUVICA
US 	436 	492 	-11.3% 	-11.3% 	- 	1,747 	1,821 	-4.0% 	-4.0% 	-
Intl 	626 	625 	0.0% 	3.4% 	-3.4% 	2,622 	2,307 	13.6% 	10.4% 	3.2%
WW 	1,062 	1,117 	-5.0% 	-3.1% 	-1.9% 	4,369 	4,128 	5.8% 	4.1% 	1.7%
ZYTIGA / abiraterone acetate
US 	23 	89 	-74.2% 	-74.2% 	- 	119 	373 	-68.1% 	-68.1% 	-
Intl 	525 	533 	-1.4% 	3.1% 	-4.5% 	2,178 	2,097 	3.9% 	1.5% 	2.4%
WW 	548 	622 	-11.8% 	-7.9% 	-3.9% 	2,297 	2,470 	-7.0% 	-9.0% 	2.0%
OTHER ONCOLOGY
US 	34 	20 	64.7% 	64.7% 	- 	110 	83 	31.7% 	31.7% 	-
Intl 	106 	183 	-42.0% 	-39.2% 	-2.8% 	458 	738 	-37.9% 	-38.7% 	0.8%
WW 	140 	202 	-31.3% 	-28.8% 	-2.5% 	568 	821 	-30.8% 	-31.5% 	0.7%
% Change 	% Change

-- 3 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	587 	592 	-0.7% 	-0.7% 	- 	2,365 	2,133 	10.9% 	10.9% 	-
Intl 	264 	273 	-3.6% 	0.8% 	-4.4% 	1,085 	1,015 	6.9% 	5.5% 	1.4%
WW 	851 	865 	-1.6% 	-0.2% 	-1.4% 	3,450 	3,148 	9.6% 	9.2% 	0.4%
OPSUMIT
US 	286 	279 	2.0% 	2.0% 	- 	1,147 	1,008 	13.7% 	13.7% 	-
Intl 	162 	173 	-6.1% 	-1.7% 	-4.4% 	672 	631 	6.6% 	5.1% 	1.5%
WW 	448 	452 	-1.1% 	0.6% 	-1.7% 	1,819 	1,639 	11.0% 	10.4% 	0.6%
UPTRAVI
US 	264 	263 	0.0% 	0.0% 	- 	1,056 	955 	10.5% 	10.5% 	-
Intl 	46 	38 	21.9% 	24.7% 	-2.8% 	181 	138 	31.1% 	27.0% 	4.1%
WW 	310 	301 	2.7% 	3.1% 	-0.4% 	1,237 	1,093 	13.1% 	12.6% 	0.5%
OTHER PULMONARY HYPERTENSION
US 	38 	49 	-20.1% 	-20.1% 	- 	163 	169 	-3.7% 	-3.7% 	-
Intl 	56 	63 	-12.2% 	-6.6% 	-5.6% 	232 	247 	-5.9% 	-5.4% 	-0.5%
WW 	94 	112 	-15.6% 	-12.4% 	-3.2% 	395 	416 	-5.0% 	-4.7% 	-0.3%
CARDIOVASCULAR / METABOLISM / OTHER
US 	813 	935 	-13.1% 	-13.1% 	- 	3,192 	3,509 	-9.0% 	-9.0% 	-
Intl 	261 	317 	-17.8% 	-16.0% 	-1.8% 	1,268 	1,369 	-7.4% 	-10.9% 	3.5%
WW 	1,074 	1,253 	-14.3% 	-13.8% 	-0.5% 	4,460 	4,878 	-8.6% 	-9.6% 	1.0%
XARELTO
US 	644 	629 	2.5% 	2.5% 	- 	2,438 	2,345 	4.0% 	4.0% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	644 	629 	2.5% 	2.5% 	- 	2,438 	2,345 	4.0% 	4.0% 	-
INVOKANA / INVOKAMET
US 	59 	159 	-63.1% 	-63.1% 	- 	308 	564 	-45.4% 	-45.4% 	-
Intl 	60 	58 	3.8% 	4.5% 	-0.7% 	254 	231 	9.9% 	5.4% 	4.5%
WW 	120 	217 	-45.1% 	-44.9% 	-0.2% 	563 	795 	-29.3% 	-30.6% 	1.3%
PROCRIT / EPREX
US 	55 	62 	-12.8% 	-12.8% 	- 	223 	277 	-19.7% 	-19.7% 	-
Intl 	58 	66 	-13.0% 	-11.7% 	-1.3% 	256 	274 	-6.8% 	-10.1% 	3.3%
WW 	113 	129 	-12.9% 	-12.2% 	-0.7% 	479 	552 	-13.3% 	-14.9% 	1.6%
OTHER
US 	55 	85 	-35.6% 	-35.6% 	- 	223 	323 	-31.0% 	-31.0% 	-
Intl 	143 	194 	-25.9% 	-23.8% 	-2.1% 	758 	864 	-12.2% 	-15.5% 	3.3%
WW 	198 	278 	-28.9% 	-27.4% 	-1.5% 	981 	1,186 	-17.3% 	-19.7% 	2.4%
TOTAL PHARMACEUTICAL
US 	7,418 	7,116 	4.2% 	4.2% 	- 	27,954 	25,735 	8.6% 	8.6% 	-
Intl 	6,870 	5,152 	33.4% 	36.9% 	-3.5% 	24,126 	19,837 	21.6% 	18.8% 	2.8%
WW 	14,288	$ 	12,268 	16.5% 	17.9% 	-1.4% 	52,080	$ 	45,572 	14.3% 	13.1% 	1.2%
% Change 	% Change

-- 4 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
MEDICAL DEVICES SEGMENT (2) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	483	$ 	433 	11.6% 	11.6% 	- 	1,836 	1,452 	26.4% 	26.4% 	-
Intl 	536 	460 	16.5% 	18.8% 	-2.3% 	2,135 	1,594 	34.0% 	29.8% 	4.2%
WW 	1,019 	893 	14.1% 	15.3% 	-1.2% 	3,971 	3,046 	30.4% 	28.2% 	2.2%
ORTHOPAEDICS
US 	1,305 	1,352 	-3.5% 	-3.5% 	- 	5,126 	4,779 	7.3% 	7.3% 	-
Intl 	851 	839 	1.5% 	3.9% 	-2.4% 	3,462 	2,984 	16.0% 	12.1% 	3.9%
WW 	2,155 	2,191 	-1.6% 	-0.7% 	-0.9% 	8,588 	7,763 	10.6% 	9.1% 	1.5%
HIPS
US 	229 	229 	0.4% 	0.4% 	- 	883 	793 	11.4% 	11.4% 	-
Intl 	151 	143 	4.9% 	6.5% 	-1.6% 	602 	487 	23.6% 	18.9% 	4.7%
WW 	380 	372 	2.1% 	2.7% 	-0.6% 	1,485 	1,280 	16.0% 	14.3% 	1.7%
KNEES
US 	208 	216 	-4.2% 	-4.2% 	- 	787 	743 	5.9% 	5.9% 	-
Intl 	135 	129 	4.6% 	6.5% 	-1.9% 	538 	427 	26.1% 	21.7% 	4.4%
WW 	342 	345 	-0.9% 	-0.2% 	-0.7% 	1,325 	1,170 	13.3% 	11.7% 	1.6%
TRAUMA
US 	467 	454 	2.8% 	2.8% 	- 	1,819 	1,648 	10.4% 	10.4% 	-
Intl 	261 	268 	-2.4% 	0.7% 	-3.1% 	1,066 	966 	10.4% 	7.1% 	3.3%
WW 	728 	722 	0.9% 	2.0% 	-1.1% 	2,885 	2,614 	10.4% 	9.2% 	1.2%
SPINE, SPORTS & OTHER
US 	401 	453 	-11.4% 	-11.4% 	- 	1,637 	1,595 	2.6% 	2.6% 	-
Intl 	304 	299 	2.0% 	4.3% 	-2.3% 	1,256 	1,104 	13.8% 	9.9% 	3.9%
WW 	706 	752 	-6.1% 	-5.2% 	-0.9% 	2,893 	2,699 	7.2% 	5.6% 	1.6%
% Change 	% Change

-- 5 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
SURGERY
US 	986 	1,002 	-1.7% 	-1.7% 	- 	3,867 	3,249 	19.0% 	19.0% 	-
Intl 	1,527 	1,427 	7.0% 	8.7% 	-1.7% 	5,945 	4,983 	19.3% 	15.6% 	3.7%
WW 	2,513 	2,429 	3.5% 	4.4% 	-0.9% 	9,812 	8,232 	19.2% 	17.0% 	2.2%
ADVANCED
US 	457 	456 	0.5% 	0.5% 	- 	1,761 	1,535 	14.9% 	14.9% 	-
Intl 	735 	660 	11.2% 	12.6% 	-1.4% 	2,861 	2,304 	24.1% 	20.0% 	4.1%
WW 	1,192 	1,116 	6.8% 	7.6% 	-0.8% 	4,622 	3,839 	20.4% 	18.0% 	2.4%
GENERAL
US 	528 	546 	-3.4% 	-3.4% 	- 	2,105 	1,714 	22.7% 	22.7% 	-
Intl 	793 	767 	3.4% 	5.3% 	-1.9% 	3,085 	2,679 	15.2% 	11.8% 	3.4%
WW 	1,321 	1,312 	0.6% 	1.7% 	-1.1% 	5,190 	4,392 	18.1% 	16.1% 	2.0%
VISION
US 	443 	397 	11.4% 	11.4% 	- 	1,857 	1,557 	19.3% 	19.3% 	-
Intl 	728 	679 	7.2% 	10.8% 	-3.6% 	2,831 	2,362 	19.8% 	18.8% 	1.0%
WW 	1,171 	1,076 	8.7% 	11.0% 	-2.3% 	4,688 	3,919 	19.6% 	19.0% 	0.6%
CONTACT LENSES / OTHER
US 	316 	289 	9.4% 	9.4% 	- 	1,398 	1,213 	15.2% 	15.2% 	-
Intl 	518 	507 	1.9% 	5.8% 	-3.9% 	2,043 	1,781 	14.7% 	14.0% 	0.7%
WW 	833 	796 	4.6% 	7.1% 	-2.5% 	3,440 	2,994 	14.9% 	14.5% 	0.4%
SURGICAL
US 	126 	108 	16.8% 	16.8% 	- 	459 	344 	33.5% 	33.5% 	-
Intl 	211 	172 	22.9% 	25.4% 	-2.5% 	788 	581 	35.7% 	33.3% 	2.4%
WW 	338 	280 	20.5% 	22.1% 	-1.6% 	1,248 	925 	34.9% 	33.4% 	1.5%
TOTAL MEDICAL DEVICES
US 	3,216 	3,184 	1.0% 	1.0% 	- 	12,686 	11,036 	14.9% 	14.9% 	-
Intl 	3,643 	3,405 	7.0% 	9.3% 	-2.3% 	14,374 	11,923 	20.6% 	17.3% 	3.3%
WW 	6,859	$ 	6,589 	4.1% 	5.3% 	-1.2% 	27,060	$ 	22,959 	17.9% 	16.2% 	1.7%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
The Company estimates that the inclusion of an additional week in the 2020 fiscal year impacted fiscal fourth quarter 2021 comparative sales growth by
approximately -4% and impacted full year fiscal 2021 comparative sales growth by approximately -1%.
% Change 	% Change

-- 6 of 6 --